Here are the DEF 14A proxy statements from Whitehawk Therapeutics, Inc. (WHWK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow WHWK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WHWK filings page.
Whitehawk Therapeutics, Inc. is holding its 2026 annual stockholder meeting virtually on June 11, 2026 at 1:00 p.m. Eastern Time. Holders of 49,428,177 common shares as of April 17, 2026 can vote online, by phone, by mail, or during the webcast.
Stockholders will elect three Class III directors to terms ending in 2029, cast an advisory vote on 2025 executive compensation, and vote on ratifying BDO USA, P.C. as independent auditor for 2026. The proxy also outlines board structure, committee memberships, director pay, and employment and severance terms for senior executives, including salary, bonus targets and equity incentives.